Direct compression tablet lines for veterinary amikacin sulfate formulations are controlled more by particle-size management than by chemical incompatibility. Amikacin sulfate is hygroscopic; incoming API from double polyethylene-lined drums is conditioned in a low-humidity weighing suite below 40% RH before weighment to prevent water uptake that changes bulk density. The unit formula contains amikacin sulfate equivalent to amikacin 50 mg, 100 mg, or 200 mg per tablet, with a lactose monohydrate or dicalcium phosphate dihydrate diluent, croscarmellose sodium 2–5% w/w, povidone K30 2–4% w/w as dry binder, and magnesium stearate 0.25–1.0% w/w. A staged geometric dilution is performed at 1:5 or 1:10 active-to-diluent before final blending in a tumble blender equipped with an intensifier bar. Blend uniformity samples are taken from 10 stratified positions; relative standard deviation above 5.0% triggers an additional screening step through a 500 µm stainless steel mesh or an extended blend time determined by assay. Final blend moisture is held below 2.0% because higher moisture produces sticking on tooling and weight variability during compression. A rotary tablet press with standard round concave tooling is operated with main compression force 25–35 kN and pre-compression force 10–15 kN; tablet hardness is adjusted to 50–80 N as an in-process upper and lower boundary. Friability is tested according to USP <1216> with a target not more than 1.0% weight loss. Uniformity of dosage units is tested by USP <905> with acceptance value not greater than 15.0. Disintegration is tested by USP <701> in water at 37 ± 2 °C within 15 min. Dissolution development uses USP <711> Apparatus 2 at 50 rpm in 900 mL water; the Q value is product-specific and derived from batch data rather than assigned as a universal figure. Where tablet weight exceeds 600 mg or the amikacin load creates flow defects, a wet granulation route with aqueous povidone K30 solution may replace direct compression; granule moisture after fluid-bed drying at inlet 60–70 °C is controlled to 1.5–2.5%. The terminal product is a non-sterile veterinary tablet packed in amber glass bottles or PVC/aluminum blisters.

What Limits Sterile-Filtration Throughput in Amikacin Sulfate Injection Lines?

Amikacin sulfate dissolves readily in Water for Injection; single-vial strengths of 50 mg/mL and 250 mg/mL are achievable without organic cosolvents. The critical control in injectable manufacture is not solubilization but pH-dependent chemical stability, endotoxin removal, and particulate load. Solution pH is adjusted with sodium citrate or dilute sulfuric acid to pH 4.0–5.5; alkaline conditions above pH 8.0 accelerate degradation, while acidic excursions below pH 3.0 increase impurity formation and reduce chemical shelf life. Nitrogen blanketing of the mixing vessel reduces oxidative discoloration; dissolved oxygen is maintained below 1.0 mg/L before filling where the line is equipped with an in-line optical oxygen probe. The bulk solution is passed through a 0.45 µm clarifying filter followed by a 0.22 µm low-protein-binding polyvinylidene fluoride or polyethersulfone filter. Differential pressure across the sterilizing filter is monitored continuously; a value above 2.0 bar typically indicates fouling by trace metal sulfates or filter extractables and requires a filter change before post-filtration integrity testing. Terminal sterilization by steam at 121 °C for 15 min is permitted only when validated assay and color data show no shift; otherwise aseptic filtration and filling in a Grade A environment are used. The finished injection is tested under USP <1> for general injectable quality, USP <788> for particulate matter with limits of 6000 particles equal to or greater than 10 µm and 600 particles equal to or greater than 25 µm per container for small-volume vials, and USP <85> for bacterial endotoxins with an endotoxin limit calculated as K/M from the maximum veterinary dose. The product is filled into 2 mL or 4 mL glass vials with butyl rubber stoppers that have been assessed for leachable amines and extractable fatty acids. In-use stability in 0.9% NaCl or 5% dextrose infusion fluids is documented in the registration dossier. Admixture with beta-lactam antibiotics in the same infusion bag must be avoided because aminoglycoside chemical inactivation can occur. Because amikacin sulfate is highly water-soluble and stable in solution, a lyophilized injection is not a first-choice format; if lyophilization is required for a combination product, the collapse temperature and frozen-state glass transition must be established by freeze-drying microscopy and modulated differential scanning calorimetry before cycle design. The terminal product is a sterile solution or, less commonly, a sterile lyophilized cake for reconstitution.

Low-fill-weight amikacin capsules present a different failure mode from tablets because the powder bed is not compacted before filling. In a size 3 or size 2 hard gelatin capsule for veterinary use, the fill mass of an amikacin sulfate blend is typically 120–250 mg, with amikacin equivalent to 50 mg, 100 mg, or 200 mg. The blend must maintain consistent bulk density so that a dosator or tamping pin fill weight stays within ±3% of target. Pre-compaction is not available in high-speed capsule machines; therefore, particle-size matching between amikacin sulfate and the diluent is the primary control. A lactose monohydrate–microcrystalline cellulose mixture at 60:40 provides adequate compressibility without producing excessive fines during transfer. Sodium starch glycolate at 2–4% w/w assists disintegration; colloidal silicon dioxide at 0.2–0.5% w/w is added when flow through the machine hopper is marginal. Lubricant level is kept at 0.5% w/w or less because higher magnesium stearate concentrations can delay dissolution in a low-dose capsule. Moisture specification is tighter than for tablets because gelatin shell integrity is sensitive; the filled capsule is conditioned at 35–45% RH before packaging. Dissolution is characterized in USP <711> Apparatus 1 at 100 rpm or Apparatus 2 at 50 rpm; the product-specific criterion is set from pilot data and not from a universal monograph value. The capsule format is suited to companion-animal dosing where oral suspension is not stable at the site of administration. The filled capsules are packed in HDPE bottles with desiccant and induction-sealed caps to limit moisture ingress below 40% RH in the headspace. The terminal product is a solid oral dosage form intended only for non-food-producing species under veterinary prescription.

Oral Powder Sachet Blending Is Dictated by Segregation Potential

A veterinary oral powder containing amikacin sulfate in a glucose or lactose carrier requires an ordered mixing sequence because the active fraction can migrate to the bottom of the packaging and produce dose failure. The carrier is selected for a sieve cut of 100–250 µm; particles outside this range increase segregation during sachet filling and transport. Amikacin sulfate is first blended with a small amount of color-matched carrier at 1:10; the pre-blend is forced through a 355 µm screen before addition to a ribbon blender or tumble blender. Total magnesium stearate or stearic acid is omitted unless flow additives are mandatory, because hydrophobic films reduce dissolution in oral mucosal or gastric fluid. Fill weight per sachet is based on a dose of 5 mg/kg to 10 mg/kg body weight in canine or equine patients, but the exact labelled dose is registration-specific. The finished powder is filled into aluminium foil laminate sachets with a moisture vapor transmission rate below 0.5 g/m²/day. Seal integrity is tested at 200–300 mbar vacuum in a leak tester. Chemical stability of the packaged powder is evaluated under 25 °C / 60% RH and 40 °C / 75% RH according to VICH stability guidance; desiccant is not always included inside the sachet but is used in the outer carton when the laminate is not the primary moisture barrier. Dissolution testing uses USP <711> with sample suspension in water at 37 °C. This format is used where solid oral dosing is required but tablet swallowing is not practical; the oral powder may be mixed with feed or molasses immediately before administration. The product is not intended for parenteral use and must be labeled as non-sterile. The terminal product is a single-dose or multi-dose oral powder packed in foil laminate sachets or bulk containers with a measuring scoop.

Premix Granulation Parameters and Carryover Control for In-Feed Administration

Feed-grade carriers for amikacin sulfate premix are selected more for electrostatic and particle-size matching than for chemical solubility. A 5% w/w amikacin activity premix on lactose monohydrate or soy hulls is coated or adsorbed onto the carrier to prevent active-rich pockets in the final feed. The manufacturing sequence includes a low-shear mixer with a chopper to break API agglomerates; mixing time is determined by homogeneity testing rather than fixed batch time. For a 100 kg pilot batch, stratified sampling at 10 locations after each 3 min interval establishes the point at which the percent relative standard deviation falls below 5.0%. The premix is discharged through a 500 µm or 800 µm mesh to remove oversized aggregates and then filled into valve-bottom paper bags with a polyethylene liner. Cross-contamination control uses a sequential flush with lactose or the major carrier at 2–5% of the mixer working volume; residual amikacin after flush is verified by a swab or rinse method with an analytical limit set from toxicological and carryover risk data. In-feed administration is normally reserved for pigs, veal calves, or poultry only where the regulatory authority has established acceptable daily intake, maximum residue limit, and withdrawal period; published data for this specific configuration is limited for amikacin, so residue depletion must be generated by the applicant. Terminal feed homogeneity is checked with 10 feed samples; the coefficient of variation should be below 5.0% before release. The premix is labeled as medicated feed and is not a direct oral dosage form. The terminal product is a medicated premix for licensed in-feed use in non-food or food-producing species only when residue data are available and approval has been granted.

When Amikacin Sulfate Is Metered via Drinking Water Proportioners

Water system compatibility must be established before a concentrated amikacin sulfate stock solution is installed in a proportioner or dosing pump. The stock solution is prepared at 25 mg/mL to 50 mg/mL in potable or softened water; hard water with total hardness above 150 mg/L as CaCO₃ may form insoluble sulfate or carbonate complexes that reduce dosing accuracy and build up in the proportioner. The solution is mixed in a closed high-density polyethylene tank and used within 24 h unless chemical stability data support longer hold times. Light protection is required because aminoglycoside solutions can darken with prolonged UV exposure; the tank is covered or a blackout jacket is used. Fluid lines are calibrated before each batch; a dosing pump with a certified flow rate of 0.5–5.0 L/h at 3–5 bar is preferred. The target drinking water concentration is calculated from the label dose and measured daily water intake; no universal concentration is assigned because water consumption varies. In development, dose-proportionality is tested at the maximum and minimum expected intake rates rather than at a fixed mg/L value. Drinking water is medicated in a primary tank and not injected directly into high-pressure branch lines unless the pump is rated for that pressure. At the end of the medication period, the water system is flushed with non-medicated water for 10–15 min to clear residual drug. This route is acceptable where the animal population is drinking normally; febrile animals with reduced water intake may receive inconsistent dosing, so labeling includes a directive to revert to parenteral administration when water consumption falls below 80% of normal. The terminal product is a bulk or multi-dose liquid formulation packaged in jerry cans or drum liners and dispatched under veterinary prescription.